Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection - PubMed (original) (raw)
. 2003 Dec;38(6):1468-76.
doi: 10.1016/j.hep.2003.09.027.
Angela J Frodsham, Branwen J W Hennig, Paul Klenerman, Suzanne Knapp, Patricia Ramaley, Jack Satsangi, Mark Wright, Lyna Zhang, Howard C Thomas, Mark Thursz, Adrian V S Hill
Affiliations
- PMID: 14647058
- DOI: 10.1016/j.hep.2003.09.027
Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection
Simon Hellier et al. Hepatology. 2003 Dec.
Abstract
The effect of host genetic variation on the outcome of hepatitis C virus (HCV) infection and its treatment is poorly understood. The chemokine receptors CCR5, CCR2, and CCR3 and their ligands, RANTES, MCP-1, MCP-2, and MIP-1alpha, are involved in the immune responses and the selective recruitment of lymphocytes to the liver in HCV infection. We studied 20 polymorphisms within these genes and investigated their association with persistent carriage of HCV, severity of liver disease, hepatic inflammation, and response to treatment in a large European cohort. Significant associations were found between CCR5-delta32 and reduced portal inflammation (P =.011, odds ratio [OR]: 2.3, 95% confidence interval [CI]: 1.09-4.84) and milder fibrosis (P =.015, OR: 1.97, 95% CI: 1.13-3.42). A promoter polymorphism at position -403 in the RANTES gene was associated with less severe portal inflammation (P =.004). An amino acid change in MCP2, Q46K, was associated with severity of fibrosis (P =.018, OR: 2.29, 95% CI: 1.14-4.58). In conclusion, our study suggests a possible role of the polymorphisms CCR5-delta32, RANTES -403, and MCP-2 Q46K in the outcome of HCV infection.
Comment in
- Chemokine systems and hepatitis C virus infection: is truth in the genes of the beholders?
Promrat K, Liang TJ. Promrat K, et al. Hepatology. 2003 Dec;38(6):1359-62. doi: 10.1016/j.hep.2003.10.008. Hepatology. 2003. PMID: 14647045 No abstract available.
Similar articles
- The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source.
Goulding C, McManus R, Murphy A, MacDonald G, Barrett S, Crowe J, Hegarty J, McKiernan S, Kelleher D. Goulding C, et al. Gut. 2005 Aug;54(8):1157-61. doi: 10.1136/gut.2004.055699. Epub 2005 Apr 29. Gut. 2005. PMID: 15863470 Free PMC article. - Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.
Promrat K, McDermott DH, Gonzalez CM, Kleiner DE, Koziol DE, Lessie M, Merrell M, Soza A, Heller T, Ghany M, Park Y, Alter HJ, Hoofnagle JH, Murphy PM, Liang TJ. Promrat K, et al. Gastroenterology. 2003 Feb;124(2):352-60. doi: 10.1053/gast.2003.50061. Gastroenterology. 2003. PMID: 12557141 - Chemokine systems and hepatitis C virus infection: is truth in the genes of the beholders?
Promrat K, Liang TJ. Promrat K, et al. Hepatology. 2003 Dec;38(6):1359-62. doi: 10.1016/j.hep.2003.10.008. Hepatology. 2003. PMID: 14647045 No abstract available. - The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection.
Zeremski M, Petrovic LM, Talal AH. Zeremski M, et al. J Viral Hepat. 2007 Oct;14(10):675-87. doi: 10.1111/j.1365-2893.2006.00838.x. J Viral Hepat. 2007. PMID: 17875002 Review. - CCR5 plays important roles in hepatitis B infection.
Sanchooli J, Sanadgol N, Kazemi Arababadi M, Kennedy D. Sanchooli J, et al. Viral Immunol. 2014 Feb;27(1):2-6. doi: 10.1089/vim.2013.0067. Epub 2014 Jan 9. Viral Immunol. 2014. PMID: 24405101 Review.
Cited by
- Diclofenac Disrupts the Circadian Clock and through Complex Cross-Talks Aggravates Immune-Mediated Liver Injury-A Repeated Dose Study in Minipigs for 28 Days.
Selvaraj S, Oh JH, Yoon S, Borlak J. Selvaraj S, et al. Int J Mol Sci. 2023 Jan 11;24(2):1445. doi: 10.3390/ijms24021445. Int J Mol Sci. 2023. PMID: 36674967 Free PMC article. - Functional Roles of Chemokine Receptor CCR2 and Its Ligands in Liver Disease.
She S, Ren L, Chen P, Wang M, Chen D, Wang Y, Chen H. She S, et al. Front Immunol. 2022 Feb 25;13:812431. doi: 10.3389/fimmu.2022.812431. eCollection 2022. Front Immunol. 2022. PMID: 35281057 Free PMC article. Review. - Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases.
Ellwanger JH, Kulmann-Leal B, Kaminski VL, Rodrigues AG, Bragatte MAS, Chies JAB. Ellwanger JH, et al. Virus Res. 2020 Sep;286:198040. doi: 10.1016/j.virusres.2020.198040. Epub 2020 May 30. Virus Res. 2020. PMID: 32479976 Free PMC article. Review. - Metabolomics as an Approach to Characterise the Contrasting Roles of CCR5 in the Presence and Absence of Disease.
Rautenbach A, Williams AA. Rautenbach A, et al. Int J Mol Sci. 2020 Feb 21;21(4):1472. doi: 10.3390/ijms21041472. Int J Mol Sci. 2020. PMID: 32098198 Free PMC article. Review. - Cenicriviroc ameliorates the severity of graft-versus-host disease through inhibition of CCR5 in a rat model of liver transplantation.
Li M, Lu C, Zhu H, Kang X, Wang F, Shao L, Lu X, Chen W, Xia X. Li M, et al. Am J Transl Res. 2019 Jun 15;11(6):3438-3449. eCollection 2019. Am J Transl Res. 2019. PMID: 31312356 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous